Nuwellis Inc. to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase

Rhea-AI Summary

Nuwellis, Inc. (Nasdaq: NUWE) announced its participation in the Inaugural Gilmartin Group Emerging Growth Company Showcase, set to occur virtually on August 31, 2022, at 10:00 am ET. Management will present details about their innovative medical device, the Aquadex SmartFlow® system, which is essential for treating fluid overload conditions. Interested parties can access the live webcast and find archived materials on the Nuwellis website post-event. This highlights Nuwellis's commitment to improving patient outcomes through cutting-edge technology.

MINNEAPOLIS, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) today announced the company will present at the upcoming Inaugural Gilmartin Group Emerging Growth Company Showcase, taking place virtually. Members of management are scheduled to present on Wednesday, August 31, 2022 at 10:00 am ET.

Interested parties can access a live webcast of the presentation directly by following this link. An archived webcast of the presentation will be available on the “Investors” section of the Nuwellis website at https://ir.nuwellis.com/ following the event.

Those parties interested in registering for the Inaugural Gilmartin Group Emerging Growth Company Showcase may do so by following this link.

About Nuwellis
Nuwellis, Inc. (Nasdaq: NUWE) is a medical device company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. The Company is focused on developing, manufacturing and commercializing the Aquadex SmartFlow^® system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, MN, with a wholly owned subsidiary in Ireland.

About the Aquadex SmartFlow System
The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.

Contact
INVESTORS:
Matt Bacso, CFA
Gilmartin Group LLC
Matt.bacso@gilmartinir.com

MEDIA:
Jessica Stebing
Health+Commerce
260-336-6202
jstebing@healthandcommerce.com

FAQ

When is Nuwellis presenting at the Gilmartin Group Emerging Growth Company Showcase?

Nuwellis is scheduled to present on August 31, 2022, at 10:00 am ET.

How can I access the Nuwellis presentation at the event?

You can access the live webcast of the Nuwellis presentation through a link provided in the press release.

What is the focus of Nuwellis as a medical device company?

Nuwellis is dedicated to transforming the lives of patients suffering from fluid overload through innovative technologies.

What is the Aquadex SmartFlow system?

The Aquadex SmartFlow system is designed for ultrafiltration therapy to remove excess fluid from patients unresponsive to traditional medical management.

Where can I find the archived webcast of the presentation?

The archived webcast will be available in the 'Investors' section of the Nuwellis website after the event.